All In Biotech

Drug Trial Radar · NCT03738423

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

129

Actual

Start

Nov 13, 2018

Primary completion

Mar 13, 2020

Study completion Jul 24, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD. Secondary objectives are to: * Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in adult patients with moderate-to-severe AD * Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe AD * Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD

Conditions

  • Atopic Dermatitis

Interventions

  • REGN3500Drug

    Administered subcutaneous (SC)

  • REGN3500-Matching PlaceboDrug

    Administered subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Time frame: Week 16
  2. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16Time frame: Week 16

Locations

89 sites in 11 countries. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Birmingham, Alabama

  • Regeneron Study Site

    Phoenix, Arizona

  • Regeneron Study Site

    Scottsdale, Arizona

  • Regeneron Study Site

    Tucson, Arizona

  • Regeneron Study Site

    Little Rock, Arkansas

  • Regeneron Study Site

    Fountain Valley, California

  • Regeneron Study Site

    Fremont, California

  • Regeneron Study Site

    Oceanside, California

  • Regeneron Study Site

    Sacramento, California

  • Regeneron Study Site

    Santa Monica, California

  • Regeneron Study Site

    Jacksonville, Florida

  • Regeneron Study Site

    Macon, Georgia

  • Regeneron Study Site

    Skokie, Illinois

  • Regeneron Study Site

    Evansville, Indiana

  • Regeneron Study Site

    Overland Park, Kansas

  • Regeneron Study Site

    Louisville, Kentucky

  • Regeneron Study Site

    Louisville, Kentucky

  • Regeneron Study Site

    Louisville, Kentucky

  • Regeneron Study Site

    Saint Joseph, Michigan

  • Regeneron Study Site

    Minneapolis, Minnesota

  • Regeneron Study Site

    Las Vegas, Nevada

  • Regeneron Study Site

    Lebanon, New Hampshire

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    Wilmington, North Carolina

  • Regeneron Study Site

    Cincinnati, Ohio

  • Regeneron Study Site

    Norman, Oklahoma

  • Regeneron Study Site

    North Charleston, South Carolina

  • Regeneron Study Site

    San Antonio, Texas

  • Regeneron Study Site

    San Antonio, Texas

  • Regeneron Study Site

    San Antonio, Texas

  • Regeneron Study Site

    Norfolk, Virginia

  • Regeneron Study Site

    Kogarah, Australia

  • Regeneron Study Site

    Melbourne, Australia

  • Regeneron Study Site

    Calgary, Alberta, Canada

  • Regeneron Study Site

    Hamilton, Ontario, Canada

  • Regeneron Study Site

    Hamilton, Ontario, Canada

  • Regeneron Study Site

    Toronto, Ontario, Canada

  • Regeneron Study Site

    Windsor, Ontario, Canada

  • Regeneron Study Site

    Verdun, Quebec, Canada

  • Regeneron Study Site

    Brno, Czechia

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.